Promising new therapies for the treatment of Alzheimer's disease have arisen from the research conducted by the Laboratory of Endocrinology, Aging and Research (http://www.wisc.edu/agingresearch/headlines.htm). Funding is required in order to keep this important research moving forward. Individuals interested in supporting the Laboratory of Endocrinology, Aging and Disease research can contact Dr. Craig Atwood (csa@medicne.wisc.edu; 608 256 1901, Ext. 11664) or the University of Wisconsin Foundation (www.uwfoundation.wisc.edu).

The University of Wisconsin Foundation is the official fund-raising and gift-receiving organization for the University of Wisconsin-Madison, and is a nonprofit, tax-exempt Wisconsin corporation.

Alzheimer's Disease Therapy

Mounting evidence suggests that leuprolide can prevent the pathological and cognitive changes associated with the disease (read abstract here). Leuprolide dramatically decreases the production of amyloid in the brains of rats (www.jbc.org/cgi/reprint/279/19/20539), and new results indicate a reduction in amyloid plaque deposition and stabilization of cognitive performance in an aged mouse model (AßPP-transgenic mice) of AD (read abstract here). These promising results support the clinical trial data and suggest that leuprolide can stabilize the cognition of individuals with Alzheimer's disease. The Laboratory of Endocrinology, Aging and Disease continues to research this and other drug candidates in its search for a treatment to Alzheimer's disease.